You're tuned in to Markets Desk, let's get you caught up on the stories moving the needle today.
Johnson and Johnson is reporting meaningful clinical progress on two fronts. In head and neck cancer, subcutaneous amivantamab posted a forty-two percent overall response rate in the OrigAMI-four trial among patients who had already exhausted immunotherapy and chemotherapy options, a notable result in a difficult-to-treat population.
Staying with J and J, the Phase three PROTEUS study delivered its final analysis on apalutamide combined with hormone therapy, administered both before and after prostate cancer surgery. The regimen showed improved outcomes across the board, reinforcing apalutamide's position as a meaningful addition to the perioperative treatment toolkit. Both readouts add clinical depth to J and J's oncology pipeline at a time when the market is watching that segment closely.
Shifting to the tech space, Nvidia has deployed three point eight billion dollars across two artificial intelligence stocks, a reminder that the chipmaker isn't simply building the infrastructure layer of the AI economy — it's also taking strategic equity positions in it. For investors, that signals where Nvidia's own leadership believes the next wave of AI value creation is concentrating.
That's the tape. Markets Desk, signing off the floor.
